ALMR vs BRKR: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALMR and BRKR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALMR and BRKR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Alamar Biosciences builds tools for measuring proteins in blood and other biofluids at concentrations conventional immunoassays struggle to see. Its core technology, NULISA, pairs antibody capture with a sequencing readout to push sensitivity far below standard ELISA methods, and the ARGO HT system, launched commercially in January 2024, automates the workflow so a lab can run hundreds of samples across a multiplexed panel. The panels are where the recurring money is: NULISAseq Neuro 220 for neurodegeneration work, Inflammation 250, and the newer Immune 340 for translational immunology, plus an eMTBR-tau blood bioassay added to the neuro panel in 2026. Customers are academic labs, biotechs and pharma research groups, more than 300 of them across 25 countries, and the company was founded in 2018 by Yuling Luo, who previously built Advanced Cell Diagnostics.

Full ALMR guide

Bruker Corporation designs and sells high-performance scientific instruments used in research, life sciences, materials science, and industrial applications. It operates through four segments: BioSpin (nuclear magnetic resonance spectroscopy and preclinical imaging), CALID (mass spectrometry and chromatography for life-science and applied markets), Nano (surface analysis and microscopy including atomic force microscopy), and BEST (superconducting magnets and X-ray detectors). The company is a recognized leader in specialized, complex applications such as structural biology, proteomics, and advanced materials, competing in what is effectively a duopoly with Thermo Fisher in high-end NMR and mass spectrometry.

Full BRKR guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ALMR drivers: Consumable pull-through per instrument; Installed base expansion.
• BRKR drivers: High-end instruments moat; Adjacent growth vectors.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers. For BRKR, bruker's largest customers are academic, government, and pharmaceutical research labs, so cuts to U.S.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALMR if you believe its drivers more; BRKR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALMR and BRKR guides.

ALMR. There is no meaningful price to earnings ratio here because the company loses money, so the market is working off revenue multiples: about 23 times trailing sales, or closer to 20 times the 2026 guide once the cash balance is netted out. That is in the range life-science tools investors pay for a platform growing north of 50% with widening gross margin, and it assumes the consumable annuity keeps building. The IPO priced at $17 in April 2026 and opened at $22.60, so the shares have roughly doubled from the offer price in four months, most of that in a single 31% session after the second-quarter report.

BRKR. Bruker beat reduced Q1 2026 expectations (non-GAAP EPS of ~$0.31 versus a ~$0.23 consensus) even as organic revenue fell, and it reaffirmed full-year guidance. The forward earnings multiple of roughly 15x to 16x reflects the market weighing a quality niche franchise against near-term research-spending softness.

Headline figures (approximate, August 2026): ALMR shows revenue (ttm) ~$100 million, with Q2 2026 at ~$29.4 million, up ~82% year over year, 2026 revenue guidance ~$116 million to $120 million, ~59% growth at the midpoint, gross margin (q2 2026) ~60%, up from ~53% a year earlier, net loss (q2 2026) ~$13.2 million, on ~$31.2 million of operating expenses (~$13.8 million R&D, ~$17.4 million SG&A); BRKR shows revenue (ttm) ~$3.46B, q1 2026 revenue ~$823M (+2.7% YoY, -4.4% organic), fy2026 revenue guidance ~$3.57B to $3.60B, fy2026 non-gaap eps guidance ~$2.10 to $2.15.

ALMR and BRKR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALMR and BRKR exposure against your real portfolio. It is not an investment adviser.